NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD
ORGO gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. ORGO gets an excellent profitability rating and is at the same time showing great financial health properties. ORGO has a decent growth rate and is not valued too expensively. These ratings could make ORGO a good candidate for quality investing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -0.19% | ||
ROE | -0.24% | ||
ROIC | 4.04% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 4.46% | ||
PM (TTM) | N/A | ||
GM | 75.99% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0.45 | ||
Altman-Z | 3.55 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.69 | ||
Quick Ratio | 3.35 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 33.67 | ||
Fwd PE | 17.82 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 92.04 | ||
EV/EBITDA | 6.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
3.03
+0.02 (+0.66%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 33.67 | ||
Fwd PE | 17.82 | ||
P/S | 0.8 | ||
P/FCF | 92.04 | ||
P/OCF | 27.05 | ||
P/B | 1 | ||
P/tB | 1.12 | ||
EV/EBITDA | 6.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -0.19% | ||
ROE | -0.24% | ||
ROCE | 5.12% | ||
ROIC | 4.04% | ||
ROICexc | 5.97% | ||
ROICexgc | 6.98% | ||
OM | 4.46% | ||
PM (TTM) | N/A | ||
GM | 75.99% | ||
FCFM | 0.87% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0.45 | ||
Debt/EBITDA | 0.02 | ||
Cap/Depr | 58.92% | ||
Cap/Sales | 2.08% | ||
Interest Coverage | 4.33 | ||
Cash Conversion | 36.86% | ||
Profit Quality | N/A | ||
Current Ratio | 3.69 | ||
Quick Ratio | 3.35 | ||
Altman-Z | 3.55 |